3 “Forever Stocks” to Hold When the Market Won't Sit Still
With so much volatility in the market, it's a good time for investors to consider stocks that they can hold for the long haul. These compounders don't have to make up a large part of your...
MRK - Merck & Co., Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$118.78
DETAILS
HIGH:
$135.00
LOW:
$90.00
MEDIAN:
$120.00
CONSENSUS:
$118.78
UPSIDE:
9.14%
Stock News
Winners & Losers: The ETF Playbook to Glide Trump's Great Healthcare Plan
Trump's Great Healthcare Plan redraws healthcare winners and losers - here's how ETFs like IHE could benefit as middlemen face pressure.
Rep. Julie Johnson Sells Merck & Co., Inc. (NYSE:MRK) Shares
Representative Julie Johnson (D-Texas) recently sold shares of Merck and Co., Inc. (NYSE: MRK). In a filing disclosed on January 15th, the Representative disclosed that they had sold between...
Bank Hapoalim BM Sells 10,100 Shares of Merck & Co., Inc. $MRK
Bank Hapoalim BM cut its holdings in shares of Merck and Co., Inc. (NYSE: MRK) by 45.2% in the undefined quarter, according to the company in its most recent disclosure with the Securities and...
Amalgamated Bank Sells 9,994 Shares of Merck & Co., Inc. $MRK
Amalgamated Bank lessened its holdings in Merck and Co., Inc. (NYSE: MRK) by 2.1% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional...
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a...
Why Merck's 32% Rally Isn't Enough to Change the Bearish View
MRK is up over 32% in three months, but declining estimates, Keytruda's upcoming LOE and Gardasil declines keep the stock sell-rated.
Is Merck Stock A Trap At $110?
Merck stock surged more than 10% in a month after management delivered a confidence shock on January 12th. They're now projecting that their next-generation drugs—treatments for cardiometabolic,...
Elevate Capital Advisors LLC Acquires New Stake in Merck & Co., Inc. $MRK
Elevate Capital Advisors LLC bought a new position in Merck and Co., Inc. (NYSE: MRK) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The...
Conning Inc. Boosts Stock Position in Merck & Co., Inc. $MRK
Conning Inc. lifted its holdings in shares of Merck and Co., Inc. (NYSE: MRK) by 1,059.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange...
Will Keytruda Continue to Aid Merck's Top Line in Q4 Earnings?
Keytruda drives over half of MRK's pharma revenues, but softer Q3 sales put investor focus on whether the blockbuster drug can lift Q4 sales performance.
Merck Lifts Long-Term Revenue Target
Merck (MRK) says it now sees up to $70 billion in new revenue opportunities by the mid-2030s, as it works to offset the expected loss of exclusivity for its blo
Merck & Co., Inc. (MRK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Merck & Co., Inc. (MRK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Merck says new growth opportunities to drive revenue of $70 billion by mid-2030s
Merck said on Monday it has raised its outlook for new growth drivers, forecasting $70 billion in revenue from these fresh businesses by the mid-2030s, as it accelerates the launch of additional...
Market Today: Banks, Big Tech, Biopharma and Energy Move on Policy and Deals
Guru Stock PicksJerome Dodson has made the following transactions:Reduce in ORLY by 3%Sold out in BLDRAdd in NTRA by 2.49%New position in INSMTweedy Browne Inte
Tempus Shares Jump After Strong Preliminary 2025 Results
Tempus AI (TEM) shares rose about 10% on Monday after the company filed preliminary, unaudited results showing roughly $1.27 billion in 2025 revenue.The filing
Wall Street Bulls Look Optimistic About Merck (MRK): Should You Buy?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm...
Tempus AI Stock Soars After Posting Triple-Digit Diagnostics Growth
Tempus AI (NASDAQ: TEM) stock rose after releasing preliminary Q4 and 2025 results, with revenue of $1.27B in 2025 and $367M in Q4.
3 Dividend Stocks to Hold for the Next 10 Years
Contrary to a common assumption, the tobacco industry isn't exactly imploding. There's still money to be made here.
The 2026 Dogs Of The Dow: 10 High-Yield Blue Chips
The Dow Jones Industrial Average itself yields modestly, but the Dogs of the Dow 2026 pack more dividend bite. The index's top payers dish up to 6.8%.
Price Targets
Merck upgraded to Outperform from Peer Perform at Wolfe Research
$135.00
(was $108.59)
Wolfe Research
Merck price target raised to $130 from $105 at UBS
$130.00
(was $110.96)
UBS
Merck upgraded to Outperform from Market Perform at BMO Capital
$130.00
(was $99.21)
BMO Capital
Merck price target raised to $102 from $100 at Morgan Stanley
$102.00
(was $100.06)
Morgan Stanley
Merck price target raised to $120 from $100 at HSBC
$120.00
(was $96.89)
Rajesh Kumar
·
HSBC
Merck price target raised to $122 from $104 at Guggenheim
$122.00
(was $100.89)
Guggenheim
Merck price target raised to $120 from $105 at Scotiabank
$120.00
(was $101.88)
Louise Chen
·
Scotiabank
Merck price target raised to $120 from $92 at Goldman Sachs
$120.00
(was $101.83)
Asad Haider
·
Goldman Sachs
Merck price target raised to $100 from $98 at Morgan Stanley
$100.00
(was $84.65)
Terence Flynn
·
Morgan Stanley
Merck downgraded to Hold from Buy at Berenberg
$90.00
(was $81.14)
Luisa Hector
·
Berenberg Bank
Merck price target lowered to $98 from $99 at Morgan Stanley
$98.00
(was $84.39)
Terence Flynn
·
Morgan Stanley
Merck price target lowered to $82 from $89 at BMO Capital
$82.00
(was $82.74)
Evan Seigerman
·
BMO Capital
Merck price target lowered to $106 from $113 at Morgan Stanley
$106.00
(was $90.74)
Terence Flynn
·
Morgan Stanley
Merck (MRK) PT Lowered to $110 at Bernstein SocGen Group as 'Gardasil overhang continues'
$110.00
(was $100.69)
Courtney Breen
·
Bernstein
Merck (MRK) PT Raised to $148 at Jefferies
$148.00
(was $98.36)
Akash Tewari
·
Jefferies
Merck (MRK) PT Lowered to $136 at BMO Capital
$136.00
(was $101.88)
Evan David Seigerman
·
BMO Capital
Merck price target lowered to $136 from $142 at UBS
$136.00
(was $108.88)
Trung Huynh
·
UBS
Merck price target lowered to $140 from $142 at Barclays
$140.00
(was $109.77)
Carter Gould
·
Barclays
Merck (MRK) PT Lowered to $147 at Jefferies
$147.00
(was $113.49)
Akash Tewari
·
Jefferies
Merck Analysts Slash Their Forecasts After Q2 Results
$142.00
(was $112.89)
Colin Bristow
·
UBS